Histopathological and immunophenotyping studies on normal and sarcoma 180-bearing mice treated with a complex homeopathic medication
29 June 2004
revised27 September 2004
accepted25 October 2004
13 December 2017 (online)
Canova is a homeopathic complex medicine, used as an immune modulator. We studied its effects in normal and sarcoma 180-bearing mice. Three control groups were also evaluated. The mice were examined at daily intervals and the tumours observed histologically. Peripheral blood was analysed by flow cytometry.
A delay in the development, and a reduction in size of the tumours, and increased infiltration by lymphoid cells, granulation tissue, and fibrosis surrounding the tumour were observed with active treatment compared to control. All animals from the treated group survived, 30% of control groups died. In 30% of treated animals, a total regression of the tumour was confirmed using light microscopy, no regression was found in the control groups. Treatment with Canova increased total numbers of leukocytes and lymphocytes. Among lymphocytes, TCD4, increased in normal-treated group and B and NK cells in S180-treated groups. The results reflect enhanced immune response of the host after treatment with Canova.
- 1 Bharti A.C, Aggarwal B.B. Nuclear factor-kappa B and cancer. its role in prevention and therapy. Biochemical Pharmacology 2002; 64: 883-888.
- 2 Schreiber H. Tumour immunology. Paul W. Fundamental Immunology. 1999. Philadelphia: Lippincott-Raven Publishers; 1237-1270.
- 3 Desoize B. Stromal reaction and tumour growth. Clinical Reviews in Oncology Hematology 2004; 49: 173-176.
- 4 Rosemberg S.A. Principles and applications of biologic therapy. De Vita V.T, Hellmann S, Rosemberg S.A. Cancer. Principles & Practice of Oncology. 1993. Philadelphia: JB Lippincott; 276-292.
- 5 Gunzer M, Jänich S, Varga G, Grabbe S. Dendritic cells and tumour immunity. Seminars in Immunology 2001; 13: 291-302.
- 6 Boura P, Kountouras J, Lygidakis N.J. Tumour immunity and immunotherapy. Hepato-Gastroenterology 2001; 48: 1040-1044.
- 7 Ballow M, Nelson R. Immunopharmacology—immunomodulation and immunotherapy. JAMA 1997; 278 (22) 2008-2017.
- 8 Melo P.S, Justo G.Z, Durán N, Haun M. Natural killer cell activity and anti-tumour effects of dehydrocrotonin and its synthetic derivatives. European Journal of Pharmacology 2004; 487: 47-54.
- 9 Klimp A.H, Vries E.G.E, Scherphof G.L, Daemen T. A potential role of macrophage activation in the treatment of cancer. Clinical Reviews in Oncology Hematology 2002; 44 (02) 143-161.
- 10 Assef M.L.M, Carneiro-Leão A.M, Moretão M.P. et al. Histological and immunohistochemical evaluation of Sarcoma 180 in mice after treatment with an α-d-glucan from the lichen Ramalina celastri . Brazilian Journal of Morphological Science 2002; 19 (02) 49-54.
- 11 Sasaki M.G.M, Mariano F.C, Gurgel L, Probst S. Estudo Clínico randomizado placebo controlado apara avaliar a eficácia e segurança do Método Canova na terapêutica de pacientes portadores de HIV/AIDS em uso de anti-retrovirais. Brazilian Journal of Infectious Disease 2001; 5 (Suppl. 01) 58..
- 12 Seligmann I.C, Lima P.D.L, Cardoso P.C.S. et al. The anticancer homeopathic composite “Canova Method” is not genotoxic for human lymphocytes in vitro . Genetics and Molecular Research 2003; 2 (02) 223-228.
- 13 Piemonte M.R, Buchi D.F. Analysis of IL-2, IFN-γ and TNF-α production, α 5 β 1 integrins and actin filaments distribution in intraperitoneal mouse macrophages treated with homeopathic medicament. Journal of Submicroscopy Cytology and Pathology 2002; 3: 255-263.
- 14 Shirai M, Izumi H, Yamagami T. Experimental transplantation models of mouse Sarcoma 180 mice for evaluation of anti-tumour drugs. Journal of Veterinarian Medical Sciences 1991; 53 (04) 707-713.
- 15 Abdullah H, Greenman J, Pimenidou A, Topping K.P, Monson J. The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells. Cancer Immunology Immunotherapy 1999; 48: 517-524.
- 16 Kawzshima A, Kawahara E, Tokuda R, Nakanishi I. Tumour necrosis factor-alpha provokes upregulation of alfa2 beta1 and alph5 beta1 integrins, and cell migration on OST osteosarcoma cells. Cell Biology International 2001; 25: 319-329.
- 17 Galis S.Z, Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis—the good, the bad and the ugly. Circulation Research 2002; 90 (03) 251-262.
- 18 Atamas S.P. Complex cytokine regulation of tissue fibrosis. Life Sciences 2002; 72 (06) 631-643.
- 19 Birkedal-Hanse H, Moore W.G.I, Bodden M.K. et al. Matrix metalloproteinases. a review. Critical Reviews in Oral Biology and Medicine 1993; 4 (02) 197-250.
- 20 Chasseing N.A, Medina P.D, Rumi L.S. Leukocyte alterations in Sarcoma 180-bearing mice. Medicina (Bueno Aires) 1988; 48: 172-178.
- 21 Okawa Y, Murata Y, Kobayashi M, Suzuki M.E, Suzuki S. Augmentation of host resistance to Candida albicans infection in ascite tumour-bearing mice. Microbiology and Immunology 1992; 36 (05) 517-521.
- 22 Ehrke M.J. Immunomodulation in cancer therapeutics. International Immunopharmacology 2003; 3: 1105-1119.